{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:53:07Z","timestamp":1792896787583,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100002947","name":"Anhui Medical University","doi-asserted-by":"publisher","award":["2023xkj163"],"award-info":[{"award-number":["2023xkj163"]}],"id":[{"id":"10.13039\/501100002947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"DOI":"10.1186\/s13063-025-08956-x","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T08:31:13Z","timestamp":1752481873000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effects of SGLT2 inhibitors on cardiac autonomic activity and ventricular remodeling in patients with acute myocardial infarction: study protocol for a clinical trial"],"prefix":"10.1186","volume":"26","author":[{"given":"Jun","family":"Wan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinglong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinglin","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,14]]},"reference":[{"issue":"25","key":"8956_CR1","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1056\/NEJMoa043938","volume":"352","author":"SD Solomon","year":"2005","unstructured":"Solomon SD, Zelenkofske S, McMurray JJ, et al. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med. 2005;352(25):2581\u20138.","journal-title":"N Engl J Med"},{"issue":"12","key":"8956_CR2","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1161\/CIRCRESAHA.116.304521","volume":"116","author":"M Hayashi","year":"2015","unstructured":"Hayashi M, Shimizu W, Albert CM. The spectrum of epidemiology underlying sudden cardiac death. Circ Res. 2015;116(12):1887\u2013906.","journal-title":"Circ Res"},{"key":"8956_CR3","doi-asserted-by":"publisher","first-page":"1012220","DOI":"10.3389\/fcvm.2022.1012220","volume":"9","author":"A Cesaro","year":"2022","unstructured":"Cesaro A, Gragnano F, Paolisso P, et al. In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: Insights from the SGLT2-I AMI PROTECT study. Front Cardiovasc Med. 2022;9:1012220.","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"8956_CR4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12933-022-01506-8","volume":"21","author":"P Paolisso","year":"2022","unstructured":"Paolisso P, Bergamaschi L, Santulli G, et al. Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry. Cardiovasc Diabetol. 2022;21(1):77.","journal-title":"Cardiovasc Diabetol"},{"key":"8956_CR5","doi-asserted-by":"publisher","first-page":"106597","DOI":"10.1016\/j.phrs.2022.106597","volume":"187","author":"P Paolisso","year":"2023","unstructured":"Paolisso P, Bergamaschi L, Gragnano F, et al. Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT Registry. Pharmacol Res. 2023;187:106597.","journal-title":"Pharmacol Res"},{"issue":"6","key":"8956_CR6","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1161\/CIRCULATIONAHA.120.052186","volume":"143","author":"MMY Lee","year":"2021","unstructured":"Lee MMY, Brooksbank KJM, Wetherall K, et al. Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation. 2021;143(6):516\u201325.","journal-title":"Circulation"},{"issue":"3","key":"8956_CR7","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.jacc.2020.11.008","volume":"77","author":"CG Santos-Gallego","year":"2021","unstructured":"Santos-Gallego CG, Vargas-Delgado AP, Requena-Ibanez JA, et al. Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction. J Am Coll Cardiol. 2021;77(3):243\u201355.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"8956_CR8","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1001\/jamacardio.2020.6827","volume":"6","author":"M Omar","year":"2021","unstructured":"Omar M, Jensen J, Ali M, et al. Associations of empagliflozin with left ventricular volumes, mass, and function in patients with heart failure and reduced ejection fraction: a substudy of the empire HF randomized clinical trial. JAMA Cardiol. 2021;6(7):836\u201340.","journal-title":"JAMA Cardiol"},{"issue":"6","key":"8956_CR9","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","volume":"5","author":"GD Lopaschuk","year":"2020","unstructured":"Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review. JACC Basic Transl Sci. 2020;5(6):632\u201344.","journal-title":"JACC Basic Transl Sci"},{"issue":"1","key":"8956_CR10","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s00395-022-00939-2","volume":"117","author":"Z Zhou","year":"2022","unstructured":"Zhou Z, Liu C, Xu S, et al. Metabolism regulator adiponectin prevents cardiac remodeling and ventricular arrhythmias via sympathetic modulation in a myocardial infarction model. Basic Res Cardiol. 2022;117(1):34.","journal-title":"Basic Res Cardiol"},{"issue":"6","key":"8956_CR11","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.jacc.2006.09.048","volume":"49","author":"S Kasama","year":"2007","unstructured":"Kasama S, Toyama T, Hatori T, et al. Effects of intravenous atrial natriuretic peptide on cardiac sympathetic nerve activity and left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol. 2007;49(6):667\u201374.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"8956_CR12","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12933-020-01127-z","volume":"19","author":"W Shimizu","year":"2020","unstructured":"Shimizu W, Kubota Y, Hoshika Y, et al. Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial. Cardiovasc Diabetol. 2020;19(1):148.","journal-title":"Cardiovasc Diabetol"},{"key":"8956_CR13","doi-asserted-by":"publisher","first-page":"e7586","DOI":"10.1136\/bmj.e7586","volume":"346","author":"A-W Chan","year":"2013","unstructured":"Chan A-W, Tetzlaff JM, G\u00f8tzsche PC, Altman DG, Mann H, Berlin J, Dickersin K, Hr\u00f3bjartsson A, Schulz KF, Parulekar WR, Krle\u017ea-Jeri\u0107 K, Laupacis A, Moher D. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586.","journal-title":"BMJ"},{"issue":"5","key":"8956_CR14","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1007\/s13300-018-0480-7","volume":"9","author":"Y Kubota","year":"2018","unstructured":"Kubota Y, Yamamoto T, Tara S, et al. Effect of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: Rationale. Diabetes Ther. 2018;9(5):2107\u201316.","journal-title":"Diabetes Ther"},{"issue":"1","key":"8956_CR15","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1097\/MJT.0000000000000450","volume":"24","author":"CA Buzea","year":"2017","unstructured":"Buzea CA, Dan GA, Dan AR, et al. Deceleration and acceleration capacities in risk stratification for arrhythmias in patients with chronic obstructive pulmonary disease. Am J Ther. 2017;24(1):e44\u201351.","journal-title":"Am J Ther"},{"issue":"5","key":"8956_CR16","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1093\/eurheartj\/ehn540","volume":"30","author":"A Bauer","year":"2009","unstructured":"Bauer A, Barthel P, Schneider R, et al. Improved stratification of autonomic regulation for risk prediction in post-infarction patients with preserved left ventricular function (ISAR-Risk). Eur Heart J. 2009;30(5):576\u201383.","journal-title":"Eur Heart J"},{"issue":"19","key":"8956_CR17","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1016\/j.jcin.2020.08.007","volume":"13","author":"Y Park","year":"2020","unstructured":"Park Y, Koh JS, Lee JH, et al. Effect of ticagrelor on left ventricular remodeling in patients with ST-segment elevation myocardial infarction (HEALING-AMI). JACC Cardiovasc Interv. 2020;13(19):2220\u201334.","journal-title":"JACC Cardiovasc Interv"},{"issue":"18","key":"8956_CR18","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1161\/01.CIR.0000036014.90197.FA","volume":"106","author":"L Bolognese","year":"2002","unstructured":"Bolognese L, Neskovic AN, Parodi G, et al. Left ventricular remodeling after primary coronary angioplasty: patterns of left ventricular dilation and long-term prognostic implications. Circulation. 2002;106(18):2351\u20137.","journal-title":"Circulation"},{"issue":"9","key":"8956_CR19","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1161\/CIRCULATIONAHA.117.033502","volume":"137","author":"KA Hicks","year":"2018","unstructured":"Hicks KA, Mahaffey KW, Mehran R, et al. 2017 Cardiovascular and stroke endpoint definitions for clinical trials. Circulation. 2018;137(9):961\u201372.","journal-title":"Circulation"},{"issue":"18","key":"8956_CR20","doi-asserted-by":"publisher","first-page":"5474","DOI":"10.1039\/D1AN00808K","volume":"146","author":"Z Yuan","year":"2021","unstructured":"Yuan Z, Wang L, Chen J, et al. Electrochemical strategies for the detection of cTnI. Analyst. 2021;146(18):5474\u201395.","journal-title":"Analyst"},{"issue":"2","key":"8956_CR21","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1515\/jomb-2016-0003","volume":"35","author":"M Radosavljevic-Radovanovic","year":"2016","unstructured":"Radosavljevic-Radovanovic M, Radovanovic N, Vasiljevic Z, et al. Usefulness of NT-proBNP in the follow-up of patients after myocardial infarction. J Med Biochem. 2016;35(2):158\u201365.","journal-title":"J Med Biochem"},{"issue":"4","key":"8956_CR22","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347\u201357.","journal-title":"N Engl J Med"},{"issue":"12","key":"8956_CR23","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089\u201398.","journal-title":"N Engl J Med"},{"issue":"4","key":"8956_CR24","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1161\/CIRCULATIONAHA.120.051783","volume":"143","author":"M Packer","year":"2021","unstructured":"Packer M, Anker SD, Butler J, et al. Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction: the EMPEROR-reduced trial. Circulation. 2021;143(4):326\u201336.","journal-title":"Circulation"},{"key":"8956_CR25","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995\u20132008.","journal-title":"N Engl J Med"},{"key":"8956_CR26","doi-asserted-by":"publisher","first-page":"1060666","DOI":"10.3389\/fphys.2023.1060666","volume":"14","author":"A Elia","year":"2023","unstructured":"Elia A, Fossati S. Autonomic nervous system and cardiac neuro-signaling pathway modulation in cardiovascular disorders and Alzheimer\u2019s disease. Front Physiol. 2023;14:1060666.","journal-title":"Front Physiol"},{"issue":"19","key":"8956_CR27","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1161\/01.CIR.0000129252.96341.8B","volume":"109","author":"LN Graham","year":"2004","unstructured":"Graham LN, Smith PA, Huggett RJ, et al. Sympathetic drive in anterior and inferior uncomplicated acute myocardial infarction. Circulation. 2004;109(19):2285\u20139.","journal-title":"Circulation"},{"issue":"10","key":"8956_CR28","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.jacc.2018.12.064","volume":"73","author":"JJ Goldberger","year":"2019","unstructured":"Goldberger JJ, Arora R, Buckley U, Shivkumar K. Autonomic nervous system dysfunction: JACC Focus Seminar. J Am Coll Cardiol. 2019;73(10):1189\u2013206.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"8956_CR29","first-page":"e48893","volume":"15","author":"V Schismenos","year":"2023","unstructured":"Schismenos V, Tzanis AA, Papadopoulos GE, Nikas D, Koniari I, Kolettis TM. Autonomic responses during acute anterior versus inferior myocardial infarction: a systematic review and meta-analysis. Cureus. 2023;15(11):e48893.","journal-title":"Cureus"},{"issue":"6","key":"8956_CR30","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1161\/CIRCRESAHA.113.302549","volume":"114","author":"MJ Shen","year":"2014","unstructured":"Shen MJ, Zipes DP. Role of the autonomic nervous system in modulating cardiac arrhythmias. Circ Res. 2014;114(6):1004\u201321.","journal-title":"Circ Res"},{"issue":"9","key":"8956_CR31","doi-asserted-by":"publisher","first-page":"664","DOI":"10.2459\/JCM.0000000000001630","volume":"25","author":"Y Jing","year":"2024","unstructured":"Jing Y, Ding Y, Fu H, et al. Empagliflozin ameliorates ventricular arrhythmias by inhibiting sympathetic remodeling via nerve growth factor\/tyrosine kinase receptor A pathway inhibition. J Cardiovasc Med (Hagerstown). 2024;25(9):664\u201373.","journal-title":"J Cardiovasc Med (Hagerstown)"},{"issue":"11","key":"8956_CR32","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1161\/CIRCRESAHA.114.302589","volume":"114","author":"VG Florea","year":"2014","unstructured":"Florea VG, Cohn JN. The autonomic nervous system and heart failure. Circ Res. 2014;114(11):1815\u201326.","journal-title":"Circ Res"},{"issue":"9523","key":"8956_CR33","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1016\/S0140-6736(06)68735-7","volume":"367","author":"A Bauer","year":"2006","unstructured":"Bauer A, Kantelhardt JW, Barthel P, et al. Deceleration capacity of heart rate as a predictor of mortality after myocardial infarction: cohort study. Lancet. 2006;367(9523):1674\u201381.","journal-title":"Lancet"},{"issue":"22","key":"8956_CR34","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"key":"8956_CR35","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.2337\/db15-1356","volume":"65","author":"E Ferrannini","year":"2016","unstructured":"Ferrannini E, Baldi S, Frascerra S, et al. Shift to fatty substrates utilization in response to sodiumglucose co-transporter-2 inhibition in nondiabetic subjects and type 2 diabetic patients. Diabetes. 2016;65:1190\u20135.","journal-title":"Diabetes"},{"issue":"5","key":"8956_CR36","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.jjcc.2017.12.004","volume":"71","author":"M Sano","year":"2018","unstructured":"Sano M. A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity. J Cardiol. 2018;71(5):471\u20136.","journal-title":"J Cardiol"},{"issue":"1","key":"8956_CR37","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1038\/s41467-020-15983-6","volume":"11","author":"SR Kim","year":"2020","unstructured":"Kim SR, Lee SG, Kim SH, et al. SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease. Nat Commun. 2020;11(1):2127.","journal-title":"Nat Commun"},{"issue":"1","key":"8956_CR38","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s00395-022-00934-7","volume":"117","author":"PE Nikolaou","year":"2022","unstructured":"Nikolaou PE, Mylonas N, Makridakis M, et al. Cardioprotection by selective SGLT-2 inhibitors in a non-diabetic mouse model of myocardial ischemia\/reperfusion injury: a class or a drug effect? Basic Res Cardiol. 2022;117(1):27.","journal-title":"Basic Res Cardiol"},{"issue":"4","key":"8956_CR39","first-page":"543","volume":"36","author":"S Kang","year":"2020","unstructured":"Kang S, Verma S, Hassanabad AF, et al. Direct effects of empagliflozin on extracellular matrix remodelling in human cardiac myofibroblasts: novel translational clues to explain EMPA-REG OUTCOME results. Can J Cardiol. 2020;36(4):543\u201353.","journal-title":"Can J Cardiol"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-08956-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-025-08956-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-08956-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T08:41:55Z","timestamp":1757234515000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-025-08956-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,14]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["8956"],"URL":"https:\/\/doi.org\/10.1186\/s13063-025-08956-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5602675\/v1","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,14]]},"assertion":[{"value":"8 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval for the research protocol in this study was obtained from the Ethics Review Committee at the Second Affiliated Hospital of Anhui Medical University (YX2024-041). All participants provided written informed consent before enrollment, which is retained by the corresponding author HL.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"There will be no personal identifying information published.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"246"}}